Quick Answer
Senti Biosciences Holdings, Inc. reported Stockholders Equity of $5.59 million for the year ending 2025.
- Senti Biosciences Holdings, Inc. showed a decrease of -78.2% in Stockholders Equity from 2024 to 2025.
- This data is from Senti Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $0.00 | Q1 2021: -$79.24 million | Q2 2021: -$6.00 million | Q2 2021: -$90.64 million | Q3 2021: -$101.37 million | Q1 2022: -$121.81 million | Q2 2022: $154.27 million | Q3 2022: $140.34 million | Q1 2023: $112.34 million | Q2 2023: $97.42 million | Q3 2023: $82.94 million | Q1 2024: $56.09 million | Q2 2024: $44.15 million | Q3 2024: $15.99 million | Q1 2025: $37.86 million | Q2 2025: $24.65 million | Q3 2025: $8.12 million.
- Over the full 7 years of available data (2020 to 2025), Senti Biosciences Holdings, Inc.'s Stockholders Equity has grown by 109.5%.
- Historical annual values: Fiscal year 2025: $5.59 million | Fiscal year 2024: $25.65 million | Fiscal year 2023: $66.91 million | Fiscal year 2022: $127.26 million | Fiscal year 2021: -$111.46 million | Fiscal year 2021: $0.00 | Fiscal year 2020: -$58.71 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: